Immix Biopharma (IMMX) Capital Expenditures (2021 - 2026)
Immix Biopharma (IMMX) posted Capital Expenditures of $32486.0 for Q1 2026, down 80.33% sequentially from $165126.0 in Q4 2025, and down 52.02% YoY from $67713.0 in Q1 2025.
Immix Biopharma (IMMX) Capital Expenditures (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Capital Expenditures for 5 years, with the latest figure at $32486.0 in Q1 2026.
- Quarterly Capital Expenditures fell 52.02% year-over-year to $32486.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $697698.0 (down 26.05% YoY) and the FY2025 annual result came in at $732925.0, down 37.77% from the prior year.
- Capital Expenditures slipped to $32486.0 in Q1 2026 per IMMX's latest filing, from $165126.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $507151.0 in Q4 2024 and troughed at $13177.0 in Q4 2023.
- A 4-year average of $195626.8 and a median of $146378.0 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures soared 3748.76% in 2024, then sank 77.57% in 2025.
- Over 4 years, Capital Expenditures stood at $13177.0 in 2023, then jumped by 3748.76% to $507151.0 in 2024, then slumped by 67.44% to $165126.0 in 2025, then sank by 80.33% to $32486.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $32486.0, $165126.0, and $372456.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 21,043.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21,043.00 |
| Jun 30, 2026 | 21,043.00 |
| Mar 31, 2026 | 32,486.00 |
| Mar 31, 2026 | 32,486.00 |
| Dec 31, 2025 | 165,126.00 |
| Dec 31, 2025 | 165,126.00 |
| Sep 30, 2025 | 372,456.00 |
| Sep 30, 2025 | 372,456.00 |
| Jun 30, 2025 | 127,630.00 |
| Jun 30, 2025 | 127,630.00 |
| Mar 31, 2025 | 67,713.00 |
| Mar 31, 2025 | 67,713.00 |
| Dec 31, 2024 | 507,151.00 |
| Dec 31, 2024 | 507,151.00 |
| Sep 30, 2024 | 271,542.00 |
| Sep 30, 2024 | 271,542.00 |
| Jun 30, 2024 | 97,074.00 |
| Jun 30, 2024 | 97,074.00 |
| Mar 31, 2024 | 301,913.00 |
| Mar 31, 2024 | 301,913.00 |